Physician profile
Crystal M Brimer
NPI 1922189844
$919,562.58
in general payments reported to CMS, 2019-2025
26 companies · $131K in 2025
The $131K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143K · 2020: $154K · 2021: $100K · 2022: $159K · 2023: $114K · 2024: $118K · 2025: $131K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $108K · Consulting Fee: $103K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $73K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $42K · Honoraria: $22K · Food and Beverage: $9,091 · Travel and Lodging: $6,945 · Entertainment: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $107,500.00 |
| Consulting Fee | $102,980.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $72,650.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $41,975.00 |
| Honoraria | $22,000.00 |
| Food and Beverage | $9,091.20 |
| Travel and Lodging | $6,944.76 |
| Entertainment | $248.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oculus, INC. | $611,601.33 | 2019-2025 | Ctr/Jenvis, Keratograph 5m, Na |
| Biotissue Holdings INC. | $103,803.05 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $87,995.08 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $52,655.46 | 2022-2025 | Miebo, Xiidra, Blink Nutritears |
| Lumenis Be INC | $18,000.00 | 2022 | |
| Shire North American Group INC | $12,605.87 | 2019 | |
| Kala Pharmaceuticals, INC. | $9,548.15 | 2020-2021 | |
| Lumenis, INC | $6,120.10 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $4,709.68 | 2019 | |
| Abbvie INC. | $4,704.31 | 2022-2025 | Vuity |
| Allergan, INC. | $3,253.29 | 2019-2022 | |
| Alcon Vision LLC | $1,314.38 | 2019-2025 | Tryptyr, Total30, Dailies Total1 |
| Optos, INC. | $665.06 | 2019-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Coopervision INC. | $468.97 | 2019-2024 | Myday Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $442.36 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $337.56 | 2019-2022 | |
| Eyevance Pharmaceuticals LLC | $221.01 | 2019-2022 | |
| Dompe US, INC. | $200.06 | 2022-2025 | Oxervate |
| Mallinckrodt Hospital Products INC. | $191.73 | 2021-2022 | |
| Oyster Point Pharma, INC. | $174.98 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Harrow Eye, LLC | $166.04 | 2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $129.26 | 2024-2025 | Xdemvy |
| New World Medical,INC. | $124.23 | 2023 | |
| Quidel Corporation | $60.41 | 2020 | |
| Rxsight INC | $45.45 | 2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Heidelberg Engineering, INC. | $24.76 | 2023 | Spectralis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Brimer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.